- Cancer Type
- Sample Type
- Results Expected
What is FoundationOne Heme?
FoundationOne Heme is a laboratory developed CGP test combining DNA sequencing of 406 genes and RNA sequencing of 265 genes for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. FoundationOne Heme detects known, novel and complex fusion events as well as other common genomic alterations (substitutions, indels, and copy number variations). The test can be used by physicians to identify targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses.
select introns profiled
- A single test that detects the four main classes of genomic alterations for hematologic cancers, sarcomas, and solid tumors where RNA sequencing is desired
- Uses both DNA and RNA sequencing for sensitive detection of translocations and fusions
- Reports tumor mutational burden (TMB) and microsatellite instability (MSI), which may inform clinical decision-making and clinical trial enrollment